Discover the changing trends in drug development and what has inspired world-leading companies to rethink their traditional models of discovery and development. And uncover how an innovation lab is creating access to technologies for start-ups to find and develop drugs using AI and computational technologies, tackling the challenge of ever-increasing costs of drug development.

This session with Mati Gill, CEO of AION Labs, and Guy Spigelman, EMEA Lead for Healthcare and Life Sciences Startups at Amazon Web Services, will give members an opportunity to learn about new collaborative models in biotech and pharma.

This is a thought-provoking opportunity for YPO members to learn about the key elements of success in the development of drugs, cutting costs and creating efficiencies using technology. Members will be asked to consider:

Where technology innovation is hitting the ground in the healthcare sector
What role AI will play as it impacts cost and time of drug development
The model of collaboration between, pharma companies, AWS, investors, and start-ups as they generate new innovative ways of improving efficiency in drug development
How this same group is subsequently reducing costs by leveraging technology
The level of open innovation between various drug companies and how the shared ideas and data overcome a conflict of interest.